Practice guidelines for the treatment of coccidioidomycosis

John N Galgiani, Neil M. Ampel, A. Catanzaro, R. H. Johnson, D. A. Stevens, P. L. Williams

Research output: Contribution to journalArticle

233 Citations (Scopus)

Abstract

Management of patients diagnosed with coccidioidomycosis involves defining the extent of infection and assessing host factors that predispose to disease severity. Patients with relatively localized acute pulmonary infections and no risk factors for complications often require only periodic reassessment to demonstrate resolution of their self-limited process. On the other hand, patients with extensive spread of infection or at a high risk of complications because of immunosuppresion or other pre-existing factors require a variety of treatment strategies that may include antifungal therapy, surgical debridement, or both. Amphotericin B is often selected for treatment of patients with respiratory failure due to Coccidioides immitis or rapidly progressive coccidioidal infections. With other more chronic manifestations of coccidioidomysis, treatment with fluconazole, itraconazole, or ketoconazole is common. Duration of therapy often ranges from many months to years, and, for some patients, chronic suppressive therapy is needed to prevent relapses.

Original languageEnglish (US)
Pages (from-to)658-661
Number of pages4
JournalClinical Infectious Diseases
Volume30
Issue number4
DOIs
StatePublished - 2000

Fingerprint

Coccidioidomycosis
Practice Guidelines
Infection
Therapeutics
Coccidioides
Ketoconazole
Itraconazole
Fluconazole
Amphotericin B
Debridement
Respiratory Insufficiency
Recurrence
Lung

ASJC Scopus subject areas

  • Immunology

Cite this

Practice guidelines for the treatment of coccidioidomycosis. / Galgiani, John N; Ampel, Neil M.; Catanzaro, A.; Johnson, R. H.; Stevens, D. A.; Williams, P. L.

In: Clinical Infectious Diseases, Vol. 30, No. 4, 2000, p. 658-661.

Research output: Contribution to journalArticle

Galgiani, JN, Ampel, NM, Catanzaro, A, Johnson, RH, Stevens, DA & Williams, PL 2000, 'Practice guidelines for the treatment of coccidioidomycosis', Clinical Infectious Diseases, vol. 30, no. 4, pp. 658-661. https://doi.org/10.1086/313747
Galgiani, John N ; Ampel, Neil M. ; Catanzaro, A. ; Johnson, R. H. ; Stevens, D. A. ; Williams, P. L. / Practice guidelines for the treatment of coccidioidomycosis. In: Clinical Infectious Diseases. 2000 ; Vol. 30, No. 4. pp. 658-661.
@article{a05a35e8a2df44e49191729c627d7040,
title = "Practice guidelines for the treatment of coccidioidomycosis",
abstract = "Management of patients diagnosed with coccidioidomycosis involves defining the extent of infection and assessing host factors that predispose to disease severity. Patients with relatively localized acute pulmonary infections and no risk factors for complications often require only periodic reassessment to demonstrate resolution of their self-limited process. On the other hand, patients with extensive spread of infection or at a high risk of complications because of immunosuppresion or other pre-existing factors require a variety of treatment strategies that may include antifungal therapy, surgical debridement, or both. Amphotericin B is often selected for treatment of patients with respiratory failure due to Coccidioides immitis or rapidly progressive coccidioidal infections. With other more chronic manifestations of coccidioidomysis, treatment with fluconazole, itraconazole, or ketoconazole is common. Duration of therapy often ranges from many months to years, and, for some patients, chronic suppressive therapy is needed to prevent relapses.",
author = "Galgiani, {John N} and Ampel, {Neil M.} and A. Catanzaro and Johnson, {R. H.} and Stevens, {D. A.} and Williams, {P. L.}",
year = "2000",
doi = "10.1086/313747",
language = "English (US)",
volume = "30",
pages = "658--661",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Practice guidelines for the treatment of coccidioidomycosis

AU - Galgiani, John N

AU - Ampel, Neil M.

AU - Catanzaro, A.

AU - Johnson, R. H.

AU - Stevens, D. A.

AU - Williams, P. L.

PY - 2000

Y1 - 2000

N2 - Management of patients diagnosed with coccidioidomycosis involves defining the extent of infection and assessing host factors that predispose to disease severity. Patients with relatively localized acute pulmonary infections and no risk factors for complications often require only periodic reassessment to demonstrate resolution of their self-limited process. On the other hand, patients with extensive spread of infection or at a high risk of complications because of immunosuppresion or other pre-existing factors require a variety of treatment strategies that may include antifungal therapy, surgical debridement, or both. Amphotericin B is often selected for treatment of patients with respiratory failure due to Coccidioides immitis or rapidly progressive coccidioidal infections. With other more chronic manifestations of coccidioidomysis, treatment with fluconazole, itraconazole, or ketoconazole is common. Duration of therapy often ranges from many months to years, and, for some patients, chronic suppressive therapy is needed to prevent relapses.

AB - Management of patients diagnosed with coccidioidomycosis involves defining the extent of infection and assessing host factors that predispose to disease severity. Patients with relatively localized acute pulmonary infections and no risk factors for complications often require only periodic reassessment to demonstrate resolution of their self-limited process. On the other hand, patients with extensive spread of infection or at a high risk of complications because of immunosuppresion or other pre-existing factors require a variety of treatment strategies that may include antifungal therapy, surgical debridement, or both. Amphotericin B is often selected for treatment of patients with respiratory failure due to Coccidioides immitis or rapidly progressive coccidioidal infections. With other more chronic manifestations of coccidioidomysis, treatment with fluconazole, itraconazole, or ketoconazole is common. Duration of therapy often ranges from many months to years, and, for some patients, chronic suppressive therapy is needed to prevent relapses.

UR - http://www.scopus.com/inward/record.url?scp=0033796766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033796766&partnerID=8YFLogxK

U2 - 10.1086/313747

DO - 10.1086/313747

M3 - Article

C2 - 10770727

AN - SCOPUS:0033796766

VL - 30

SP - 658

EP - 661

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -